Calvin Cohen

Summary

Publications

  1. ncbi request reprint First-line treatment in HIV: many paths to success
    Calvin Cohen
    CRI New England, Harvard Vanguard Medical Associates, and Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 33:S29-38; quiz S39, 41-2. 2003
  2. ncbi request reprint A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 16:579-88. 2002
  3. ncbi request reprint Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations
    Calvin J Cohen
    Community Research Initiative of New England, Boston, Massachusetts, USA
    AIDS Read 15:528-32, 537-8. 2005
  4. ncbi request reprint Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  5. doi request reprint Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
    Calvin J Cohen
    Calvin J Cohen, Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 27:939-50. 2013
  6. doi request reprint Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA, USA
    J Acquir Immune Defic Syndr 60:33-42. 2012
  7. pmc Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Susan Swindells
    HIV Clinic, University of Nebraska Medical Center, Omaha, NE, USA
    BMC Infect Dis 5:23. 2005
  8. doi request reprint Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial
    Calvin J Cohen
    Community Research Initiative of New England, Boston, Massachusetts 02215 3319, USA
    AIDS 23:423-6. 2009
  9. doi request reprint Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen
    Calvin Cohen
    Community Research Initiative of New England, Boston, MA, USA
    HIV Clin Trials 10:116-24. 2009
  10. ncbi request reprint Successful HIV treatment: lessons learned
    Calvin J Cohen
    Community Research Initiative of New England, 23 Miner St, Boston, MA 02215 3319, USA
    J Manag Care Pharm 12:S6-11. 2006

Detail Information

Publications36

  1. ncbi request reprint First-line treatment in HIV: many paths to success
    Calvin Cohen
    CRI New England, Harvard Vanguard Medical Associates, and Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 33:S29-38; quiz S39, 41-2. 2003
  2. ncbi request reprint A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 16:579-88. 2002
    ..To compare the effect of treatment decisions guided by phenotypic resistance testing (PRT) or standard of care (SOC) on short-term virological response...
  3. ncbi request reprint Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations
    Calvin J Cohen
    Community Research Initiative of New England, Boston, Massachusetts, USA
    AIDS Read 15:528-32, 537-8. 2005
    ..Until future studies define the optimal approach, an evaluation of cardiovascular risk factors and treatment of those risk factors according to evidence-based guidelines are warranted...
  4. ncbi request reprint Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  5. doi request reprint Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
    Calvin J Cohen
    Calvin J Cohen, Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 27:939-50. 2013
    ..In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented...
  6. doi request reprint Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA, USA
    J Acquir Immune Defic Syndr 60:33-42. 2012
    ..Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz...
  7. pmc Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Susan Swindells
    HIV Clinic, University of Nebraska Medical Center, Omaha, NE, USA
    BMC Infect Dis 5:23. 2005
    ....
  8. doi request reprint Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial
    Calvin J Cohen
    Community Research Initiative of New England, Boston, Massachusetts 02215 3319, USA
    AIDS 23:423-6. 2009
    ..Etravirine demonstrated higher efficacy than control, irrespective of the number of detectable nonnucleoside reverse transcriptase inhibitor-resistance-associated mutations at baseline or active background antiretrovirals...
  9. doi request reprint Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen
    Calvin Cohen
    Community Research Initiative of New England, Boston, MA, USA
    HIV Clin Trials 10:116-24. 2009
    ..The options for constructing regimens active against multidrug-resistant virus have expanded...
  10. ncbi request reprint Successful HIV treatment: lessons learned
    Calvin J Cohen
    Community Research Initiative of New England, 23 Miner St, Boston, MA 02215 3319, USA
    J Manag Care Pharm 12:S6-11. 2006
    ..To review current insights concerning treatment of human immunodeficiency virus (HIV)...
  11. doi request reprint Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    Lancet 378:229-37. 2011
    ..We aimed to assess non-inferiority of rilpivirine to efavirenz in a phase 3 trial with common background nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs)...
  12. ncbi request reprint Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    J Acquir Immune Defic Syndr 37:1140-6. 2004
    ..Enfuvirtide in addition to an OB regimen does not adversely affect and may improve HRQoL when self-administered for up to 24 weeks by treatment-experienced, HIV-1-infected individuals...
  13. ncbi request reprint Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks
    Calvin Cohen
    Community Research Initiative of New England, Boston, Massachusetts 02215, USA
    HIV Clin Trials 4:347-57. 2003
    ..Enfuvirtide is the first of a new class of antiretrovirals called the fusion inhibitors. It is administered twice daily by self-injection. This study assessed patient acceptance of enfuvirtide self-injection...
  14. ncbi request reprint Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients
    James Hellinger
    CRI of New England, Boston and Springfield, MA, USA
    HIV Clin Trials 6:107-17. 2005
    ..Effective, well-tolerated nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens are therefore needed...
  15. doi request reprint Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
    Paul E Sax
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 379:2439-48. 2012
    ..We compared the efficacy and safety of EVG/COBI/FTC/TDF with standard of care-co-formulated efavirenz (EFV)/FTC/TDF-as initial treatment for HIV infection...
  16. ncbi request reprint Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care
    Calvin Cohen
    CRI New England, 23 Miner Street, Boston, Massachusetts 02215 3318, USA
    J Int Assoc Physicians AIDS Care (Chic) 1:141-5. 2002
    ..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee...
  17. doi request reprint Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial
    Calvin Cohen
    Community Research Initiative of New England, Boston, Massachusetts, USA
    HIV Clin Trials 11:239-47. 2010
    ..In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) boosted with RTV 100 mg (FPV/r100) or with RTV 200 mg (FPV/r200) daily...
  18. ncbi request reprint Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
    Calvin Cohen
    aCommunity Research Initiative of New England, Boston, Massachusetts bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cHospital La Paz, Madrid, Spain dHIV Program Hennepin County Medical Center, Minneapolis, Minnesota, USA eUniversity Medical Center Hamburg Eppendorf, Hamburg, Germany fHoldsworth House Medical Practice, Darlinghurst, New South Wales, Australia gDepartment of Infectious Disease, Kaiser Los Angeles Medical Center, Los Angeles, California, USA hNorth Manchester General Hospital, Manchester, UK iGilead Sciences, Foster City, California, USA
    AIDS 28:989-97. 2014
    ....
  19. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  20. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  21. ncbi request reprint Update on antiretroviral therapy: the 15th CROI
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 18:273-8, C3. 2008
  22. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  23. doi request reprint Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study
    Calvin J Cohen
    Community Research Initiative, New England and Harvard Vanguard Medical Associates, Boston, Massachusetts, USA
    Pharmacotherapy 28:314-22. 2008
    ..To evaluate the short-term (12 wks) safety and tolerability of a once-daily, fixed-dose abacavir-lamivudine combination versus twice-daily dosing of the separate components, both with background antiretroviral therapy...
  24. ncbi request reprint Advances in HIV therapeutics: the 14th CROI
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 17:268-70, 272-4, 283-6. 2007
  25. ncbi request reprint Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
    Jeffrey P Nadler
    Hillsborough County Health Department, University of South Florida, Tampa, FL 33602, USA
    AIDS 21:F1-10. 2007
    ....
  26. ncbi request reprint Recent developments in HIV therapeutics
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 17:162-6, C3. 2007
  27. ncbi request reprint Antiretroviral rounds. First holiday was a disaster: should she take another?
    Lydia Estanislao
    Mount Sinai Medical Center, New York City, USA
    AIDS Clin Care 16:40-1. 2004
  28. ncbi request reprint XVI International AIDS Conference: Part 1
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:517-21. 2006
  29. ncbi request reprint Antiretroviral therapy: the "when to start" debates
    Calvin J Cohen
    Clin Infect Dis 39:1705-8. 2004
  30. ncbi request reprint T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, California, USA
    J Infect Dis 191:1155-63. 2005
    ..T-1249 is a 39-amino acid synthetic peptide fusion inhibitor (FI) shown to preserve antiretroviral activity in vitro against human immunodeficiency virus (HIV) isolates that have decreased susceptibility to enfuvirtide (ENF)...
  31. ncbi request reprint Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
    Sue J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115 5924, USA
    Arch Intern Med 162:921-8. 2002
    ....
  32. ncbi request reprint Considerations in selecting protease inhibitor therapy
    Brian A Boyle
    Weill Medical College of Cornell University, New York, NY 10021, USA
    AIDS Rev 6:218-25. 2004
    ..Protease inhibitor characteristics and patient preferences should be considered in selecting the protease inhibitor that maximizes the opportunity for long-term efficacy and tolerability of highly active antiretroviral therapy...
  33. ncbi request reprint Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids
    Calvin J Cohen
    Community Research Initiative of New England, Boston, Massachusetts, USA
    AIDS Read 15:462-5, 470-1, 474, 477. 2005
    ..Balancing the efficacy of boosted PI combinations and their toxicity relative to elevations in lipid levels is critical to their success as components of HAART...
  34. ncbi request reprint XVI International AIDS Conference: Part 2
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:581-4, 591-2. 2006
  35. ncbi request reprint Editorial comment: impact of darunavir for salvage therapy
    Brian A Boyle
    AIDS Read 17:160-1. 2007
  36. ncbi request reprint Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    HIV Clin Trials 8:19-23. 2007
    ....